biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by KayakerBCon Aug 05, 2016 3:03pm

74 Views

Post# 25115109

RE:RE:Expiring options

digitel: That's ~$24 million in less than 5 months using jd's end of year target price, and with the options at a weighted average price of $.52 all they have to put up is $692,000. And remember there is no scientific risk and diversified licensing opportunities.

What are they going to do with the options?

Jeepers, I guess that question would make a little bit of sense if there really was no "scientific risk" (whatever that is) and JD held all those options (and had buckets of free cash). Otherwise, not so much.

Just buy your shares back and all these issues will disappear as they always do.

Bullboard Posts

WINNERS of the COP 29: Siemens Energy, Plug Power, dynaCERT!